Gemtuzumab ozogamicin (Mylotarg) has therapeutic activity against CD33 acute lymphoblastic leukaemias in vitro and in vivo.
about
The Polo-Like Kinase 1 (PLK1) inhibitor NMS-P937 is effective in a new model of disseminated primary CD56+ acute monoblastic leukaemiaClinicopathological and prognostic characteristics of CD33-positive multiple myeloma.Recent advances in targeted therapy of human myelogenous leukaemia.The role of gemtuzumab ozogamicin in acute leukaemia therapy.Xenograft models for the preclinical evaluation of new therapies in acute leukemia.Adult T-cell acute lymphoblastic leukemia: prognostic impact of myeloid-associated antigens.Pharmacogenomic considerations of xenograft mouse models of acute leukemia.Pharmacokinetics, pharmacodynamics and physiologically-based pharmacokinetic modelling of monoclonal antibodies.Using the Lessons Learned From the Clinic to Improve the Preclinical Development of Antibody Drug Conjugates
P2860
Q27335047-C7B08461-CA3D-4CB9-894C-1F0BE4F716CAQ33371875-377E3309-0A81-4D32-99C8-6F9368CA8AB6Q36318531-AECD7CE1-49D9-4E22-8992-72779A30C687Q36367816-EEC251C5-F1B7-4322-B2A6-8325E80CB275Q36799846-FFAB93DE-B256-491D-A1E4-18DA40E78A73Q37810105-6344B0C7-F91C-484F-977B-206F7A9B5583Q38061500-165CAECF-E6FF-4E3F-9FD4-43BBEC3C68E0Q38072598-D11811FA-1D1A-4EFF-BD7C-D61835E8787AQ38262066-A3939548-C0D2-4A03-B40B-840159CA403F
P2860
Gemtuzumab ozogamicin (Mylotarg) has therapeutic activity against CD33 acute lymphoblastic leukaemias in vitro and in vivo.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
Gemtuzumab ozogamicin (Mylotar ...... ukaemias in vitro and in vivo.
@en
type
label
Gemtuzumab ozogamicin (Mylotar ...... ukaemias in vitro and in vivo.
@en
prefLabel
Gemtuzumab ozogamicin (Mylotar ...... ukaemias in vitro and in vivo.
@en
P2093
P2860
P50
P1476
Gemtuzumab ozogamicin (Mylotar ...... eukaemias in vitro and in vivo
@en
P2093
P2860
P304
P356
10.1111/J.1365-2141.2004.05322.X
P407
P577
2005-02-01T00:00:00Z